Alexza Pharmaceuticals (ALXA) 2.07 $ALXA
Insights From the Pharmaceutical Space: New Research on Alcobra, Alder, Aldeyra, Alexion, Alexza
PR Newswire - Tue Feb 03, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alcobra (NASDAQ: ADHD), Alder (NASDAQ: ALDR), Aldeyra (NASDAQ: ALDX), Alexion (NASDAQ: ALXN), and Alexza (NASDAQ: ALXA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALDR: 26.06 (+0.18), ALDX: 11.01 (-0.25), ADHD: 6.92 (+0.73), ALXN: 182.29 (+6.02), ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals Initiates Phase 2a Study of AZ-002 (Staccato® alprazolam) in Epilepsy Patients
PR Newswire - Thu Jan 22, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiated a Phase 2a study of AZ-002 (Staccato® alprazolam), which is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS). ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs.
ALXA: 2.07 (+0.09)
Nasdaq stocks posting largest volume increases
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
AGEN: 5.03 (-0.01), TFSC: 9.43 (+0.02), GMLP: 28.17 (+0.45), EOPN: 8.55 (-0.01), EML: 20.17 (-0.02), ALXA: 2.07 (+0.09)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 11:47AM CST
EOPN: 8.55 (-0.01), ADHD: 6.92 (+0.73), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37), ALXA: 2.07 (+0.09), PRTO: 10.45 (unch), AGEN: 5.03 (-0.01), ARGS: 8.35 (-0.12), TOPS: 1.14 (+0.02), HILL: 4.42 (+0.06), EDAP: 3.55 (+0.13), CTSO: 8.20 (+0.18), VLCCF: 4.15 (-0.06), SCYX: 9.48 (+0.07), VIMC: 8.59 (-0.08), SBLK: 4.48 (+0.15), DCTH: 1.14 (+0.04), IDN: 1.43 (-0.01)
The little guys are running this morning
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 9:22AM CST
ALXA: 2.07 (+0.09)
Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVE®
PR Newswire - Tue Dec 16, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it amended its commercial Manufacturing and Supply Agreement ("Supply Agreement"
with Autoliv ASP Inc., the North American subsidiary of Sweden-based Autoliv Inc. Autoliv manufactures chemical heat packages, a key component of Alexza's single-dose Staccato® system, including Alexza's commercial product ADASUVE (Staccato loxapine).
ALV: 113.36 (-0.26), ALXA: 2.07 (+0.09)
Diario Medico Names ADASUVE® in its "Best Ideas of 2014"
PR Newswire - Thu Dec 11, 9:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that the Spanish-based publication Diario Medico included ADASUVE® (Staccato® loxapine) in its "Best Ideas of 2014" awards. The Best Ideas awards by Diario Medico acknowledge the daily work of persons, institutions or enterprises that contributed to the improvement of medicine, healthcare, and public health during the previous year. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, and the Commonwealth of Independent States countries.
ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals Announces Presentation at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is presenting at the Stifel 2014 Healthcare Conference, to be held November 18-19, 2014 at The New York Palace Hotel in New York.
ALXA: 2.07 (+0.09)
Alexza continues down move after Q3 miss
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:57AM CST
ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals' (ALXA) CEO Thomas King on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:17PM CST
ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals (ALXA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:55PM CST
ALXA: 2.07 (+0.09)
Alexza Pharma misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:44PM CST
ALXA: 2.07 (+0.09)
Alexza Reports 2014 Third Quarter Financial Results
PR Newswire - Wed Nov 05, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2014. The net loss for the third quarter was $13.3 million compared to $12.4 million during the same quarter in 2013. The net loss for the nine months ended September 30, 2014 and 2013 was $30.0 million and $33.9 million, respectively. At September 30, 2014, Alexza had consolidated cash, cash equivalents, marketable securities, and restricted cash of $39.0 million.
ALXA: 2.07 (+0.09)
Global Panic Disorders Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gm823g/panic_disorders) has announced the addition of the "Panic Disorders Global Clinical Trials Review, H2, 2014" report to their offering. Panic Disorders Global Clinical Trials Review, H2, 2014" provides data on the Panic Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Panic Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Panic Disorders. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - GlaxoSmithKline plc - ZonMw - Bluefish Pharmaceuticals AB - Teva Pharmaceutical Industries Limited - Alexza Pharmaceuticals, Inc. - Actavis plc - Abiogen Pharma S.p.A. Clinical Trial Overview of Top Institutes / Government - National Institute of Mental Health - Massachusetts General Hospital - The University of New South Wales - Charite - Universitatsmedizin Berlin - University of Pittsburgh - Samsung Medical Center - Maastricht University Medical Center - Karolinska Institute - Federal University of Rio de Janeiro - Maastricht University For more information visit http://www.researchandmarkets.com/research/gm..._disorders
PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), ALXA: 2.07 (+0.09)
Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals
at The Street - Mon Oct 27, 3:40PM CDT
Birinyi Associates president Laszlo Biriny opined that maybe the economy will catch up and the stock market may not have strong gains going forwardThe stock markets in the United States fluctuated on ...
VTAE: 14.40 (+0.82), AAPL: 127.08 (+0.62), ALXA: 2.07 (+0.09)
Alexza and Grupo Ferrer amend commercial partnership
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 9:25AM CDT
ALXA: 2.07 (+0.09)
Alexza and Ferrer Expand ADASUVE® Partnership
PR Newswire - Mon Oct 27, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that they have amended their agreement for ADASUVE® (Staccato® loxapine). Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America and the Commonwealth of Independent States countries (the Ferrer Territory). Ferrer and Alexza have agreed that Ferrer will purchase 2 million shares of Alexza common stock for $4.00 per share, thereby becoming the Company's largest shareholder. The purchase represents a combination of new investment and consideration for the elimination of certain future potential milestone payments under the agreement.
ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals Provides Update on ADASUVE® U.S. Commercial Progress
PR Newswire - Thu Oct 09, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on the U.S. commercial progress with ADASUVE® (loxapine) inhalation powder (Staccato® loxapine). Teva Pharmaceutical Industries Ltd. is Alexza's commercial partner for ADASUVE in the United States. Teva and Alexza announced the commencement of the U.S. launch of ADASUVE in March 2014.
TEVA: 56.77 (-0.58), ALXA: 2.07 (+0.09)
Alexza to Report 2014 Third Quarter Financial Results on Wednesday, November 5, 2014
PR Newswire - Wed Oct 08, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended September 30, 2014 on Wednesday, November 5, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
ALXA: 2.07 (+0.09)
Insights From the Pharmaceutical Space: New Research on Alcobra, Alder, Aldeyra, Alexion, Alexza
PR Newswire - Tue Feb 03, 7:20AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Alcobra (NASDAQ: ADHD), Alder (NASDAQ: ALDR), Aldeyra (NASDAQ: ALDX), Alexion (NASDAQ: ALXN), and Alexza (NASDAQ: ALXA). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
ALDR: 26.06 (+0.18), ALDX: 11.01 (-0.25), ADHD: 6.92 (+0.73), ALXN: 182.29 (+6.02), ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals Initiates Phase 2a Study of AZ-002 (Staccato® alprazolam) in Epilepsy Patients
PR Newswire - Thu Jan 22, 8:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has initiated a Phase 2a study of AZ-002 (Staccato® alprazolam), which is being developed for the management of epilepsy in patients with acute repetitive seizures (ARS). ARS occurs in a subset of patients with epilepsy who regularly experience breakthrough seizures, despite treatment with a regular regimen of anti-epileptic drugs.
ALXA: 2.07 (+0.09)
Nasdaq stocks posting largest volume increases
AP - Fri Jan 09, 7:18PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
AGEN: 5.03 (-0.01), TFSC: 9.43 (+0.02), GMLP: 28.17 (+0.45), EOPN: 8.55 (-0.01), EML: 20.17 (-0.02), ALXA: 2.07 (+0.09)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 11:47AM CST
EOPN: 8.55 (-0.01), ADHD: 6.92 (+0.73), CNAT: 5.92 (+0.10), ADMP: 6.50 (-0.01), FIVE: 33.01 (+0.11), TESO: 11.37 (+0.37), ALXA: 2.07 (+0.09), PRTO: 10.45 (unch), AGEN: 5.03 (-0.01), ARGS: 8.35 (-0.12), TOPS: 1.14 (+0.02), HILL: 4.42 (+0.06), EDAP: 3.55 (+0.13), CTSO: 8.20 (+0.18), VLCCF: 4.15 (-0.06), SCYX: 9.48 (+0.07), VIMC: 8.59 (-0.08), SBLK: 4.48 (+0.15), DCTH: 1.14 (+0.04), IDN: 1.43 (-0.01)
The little guys are running this morning
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 9:22AM CST
ALXA: 2.07 (+0.09)
Alexza Amends Autoliv Agreement for Heat Packages Used in ADASUVE®
PR Newswire - Tue Dec 16, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced that it amended its commercial Manufacturing and Supply Agreement ("Supply Agreement"
with Autoliv ASP Inc., the North American subsidiary of Sweden-based Autoliv Inc. Autoliv manufactures chemical heat packages, a key component of Alexza's single-dose Staccato® system, including Alexza's commercial product ADASUVE (Staccato loxapine). ALV: 113.36 (-0.26), ALXA: 2.07 (+0.09)
Diario Medico Names ADASUVE® in its "Best Ideas of 2014"
PR Newswire - Thu Dec 11, 9:00AM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that the Spanish-based publication Diario Medico included ADASUVE® (Staccato® loxapine) in its "Best Ideas of 2014" awards. The Best Ideas awards by Diario Medico acknowledge the daily work of persons, institutions or enterprises that contributed to the improvement of medicine, healthcare, and public health during the previous year. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, and the Commonwealth of Independent States countries.
ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals Announces Presentation at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 06, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it is presenting at the Stifel 2014 Healthcare Conference, to be held November 18-19, 2014 at The New York Palace Hotel in New York.
ALXA: 2.07 (+0.09)
Alexza continues down move after Q3 miss
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:57AM CST
ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals' (ALXA) CEO Thomas King on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 9:17PM CST
ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals (ALXA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:55PM CST
ALXA: 2.07 (+0.09)
Alexza Pharma misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 3:44PM CST
ALXA: 2.07 (+0.09)
Alexza Reports 2014 Third Quarter Financial Results
PR Newswire - Wed Nov 05, 3:05PM CST
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today reported financial results for the quarter ended September 30, 2014. The net loss for the third quarter was $13.3 million compared to $12.4 million during the same quarter in 2013. The net loss for the nine months ended September 30, 2014 and 2013 was $30.0 million and $33.9 million, respectively. At September 30, 2014, Alexza had consolidated cash, cash equivalents, marketable securities, and restricted cash of $39.0 million.
ALXA: 2.07 (+0.09)
Global Panic Disorders Clinical Trials Review, H2, 2014
M2 - Tue Oct 28, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gm823g/panic_disorders) has announced the addition of the "Panic Disorders Global Clinical Trials Review, H2, 2014" report to their offering. Panic Disorders Global Clinical Trials Review, H2, 2014" provides data on the Panic Disorders clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Panic Disorders. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Panic Disorders. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies - Pfizer Inc. - GlaxoSmithKline plc - ZonMw - Bluefish Pharmaceuticals AB - Teva Pharmaceutical Industries Limited - Alexza Pharmaceuticals, Inc. - Actavis plc - Abiogen Pharma S.p.A. Clinical Trial Overview of Top Institutes / Government - National Institute of Mental Health - Massachusetts General Hospital - The University of New South Wales - Charite - Universitatsmedizin Berlin - University of Pittsburgh - Samsung Medical Center - Maastricht University Medical Center - Karolinska Institute - Federal University of Rio de Janeiro - Maastricht University For more information visit http://www.researchandmarkets.com/research/gm..._disorders
PFE: 34.64 (-0.23), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), ALXA: 2.07 (+0.09)
Market News: Apple Inc, Vitae Pharmaceuticals, Alexza Pharmaceuticals
at The Street - Mon Oct 27, 3:40PM CDT
Birinyi Associates president Laszlo Biriny opined that maybe the economy will catch up and the stock market may not have strong gains going forwardThe stock markets in the United States fluctuated on ...
VTAE: 14.40 (+0.82), AAPL: 127.08 (+0.62), ALXA: 2.07 (+0.09)
Alexza and Grupo Ferrer amend commercial partnership
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 9:25AM CDT
ALXA: 2.07 (+0.09)
Alexza and Ferrer Expand ADASUVE® Partnership
PR Newswire - Mon Oct 27, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) and Grupo Ferrer Internacional, S.A. (Ferrer) announced today that they have amended their agreement for ADASUVE® (Staccato® loxapine). Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America and the Commonwealth of Independent States countries (the Ferrer Territory). Ferrer and Alexza have agreed that Ferrer will purchase 2 million shares of Alexza common stock for $4.00 per share, thereby becoming the Company's largest shareholder. The purchase represents a combination of new investment and consideration for the elimination of certain future potential milestone payments under the agreement.
ALXA: 2.07 (+0.09)
Alexza Pharmaceuticals Provides Update on ADASUVE® U.S. Commercial Progress
PR Newswire - Thu Oct 09, 3:05PM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on the U.S. commercial progress with ADASUVE® (loxapine) inhalation powder (Staccato® loxapine). Teva Pharmaceutical Industries Ltd. is Alexza's commercial partner for ADASUVE in the United States. Teva and Alexza announced the commencement of the U.S. launch of ADASUVE in March 2014.
TEVA: 56.77 (-0.58), ALXA: 2.07 (+0.09)
Alexza to Report 2014 Third Quarter Financial Results on Wednesday, November 5, 2014
PR Newswire - Wed Oct 08, 8:00AM CDT
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended September 30, 2014 on Wednesday, November 5, 2014, following the close of the U.S. financial markets. The Company will also host an investor conference call and live webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to provide a company update and discuss the financial results.
ALXA: 2.07 (+0.09)
